Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221766 · ClinicalTrials.gov registry record
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
A clinical trial of Graft Vs Host Disease and Chronic Graft vs. Host Disease, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 12
- Enrollment target
- 2
- Study locations
NCT01221766 is a study of Graft Vs Host Disease and Chronic Graft vs. Host Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants, below the 138-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01221766, a study of Graft Vs Host Disease and Chronic Graft vs. Host Disease, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease. This information may help us treat patients like you in the future.
Conditions Studied
Study Locations (2)
Massachusetts
- Children's Hospital Boston - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221766
The ClinicalTrials.gov registry entry for NCT01221766 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (91% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01221766 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01221766 about?
NCT01221766 is a clinical study titled "Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease". This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails. We are interested in knowing if hair and nail problems predict worse disease. This information may help us treat patients like you in the future.
What is the current status of trial NCT01221766?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2010-09. Estimated completion is 2014-10.
What conditions does trial NCT01221766 study?
This clinical trial studies the following conditions: Graft Vs Host Disease, Chronic Graft vs. Host Disease, cGVHD.
Who is sponsoring clinical trial NCT01221766?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01221766 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RECRUITING
-
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
RECRUITING · NA
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Graft Vs Host Disease
All registered trials for this condition
Chronic Graft vs. Host Disease
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.